UPSHER-SMITH LABORATORIES
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1919-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.upsher-smith.com/
Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Upsher-Smith Laboratories
- Target Recruit Count
- 132
- Registration Number
- NCT04748601
- Locations
- 🇺🇸
Upsher-Smith Clinical Trial Site #5, Birmingham, Alabama, United States
🇺🇸Upsher-Smith Clinical Trial Site #15, La Jolla, California, United States
🇺🇸Upsher-Smith Clinical Trials Site #3, Aurora, Colorado, United States
Vogelxo(R) ABPM Study in Hypogandal Men
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Upsher-Smith Laboratories
- Target Recruit Count
- 122
- Registration Number
- NCT04558567
- Locations
- 🇺🇸
Upsher-Smith Clinical Trial Site #6, Birmingham, Alabama, United States
🇺🇸Upsher-Smith Clinical Trial Site #2, Anaheim, California, United States
🇺🇸Upsher-Smith Clinical Trial Site #1, Miami, Florida, United States
An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)
- Conditions
- Migraine Headaches
- Interventions
- Other: Sumatriptan Placebo Nasal Spray
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Upsher-Smith Laboratories
- Target Recruit Count
- 107
- Registration Number
- NCT02856802
- Locations
- 🇺🇸
Site 30, San Diego, California, United States
🇺🇸Site 11, Santa Monica, California, United States
🇺🇸Site 31, Boston, Massachusetts, United States
Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Upsher-Smith Laboratories
- Target Recruit Count
- 210
- Registration Number
- NCT01191086
Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Upsher-Smith Laboratories
- Target Recruit Count
- 249
- Registration Number
- NCT01142193
- Prev
- 1
- 2
- Next
News
Bora Pharmaceuticals Acquires Pyros Pharmaceuticals, Expanding Rare Disease Portfolio
Bora Pharmaceuticals has acquired Pyros Pharmaceuticals, a U.S.-based company focused on developing treatments for rare diseases, including infantile spasms.